Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19376854 | 0.91 | RAB9A (0.53) | NPC1RAB9ACSF1REPHX1EPHX2 | |
| SCHEMBL19376847 | 0.90 | RAB9A (0.54) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376862 | 0.89 | RAB9A (0.53) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376853 | 0.88 | KDR (0.55) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376908 | 0.87 | RAB9A (0.54) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376843 | 0.82 | RAF1 (0.56) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL9183591 | 0.82 | RAB9A (0.67) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376884 | 0.82 | RAB9A (0.56) | NPC1RAB9ACSF1RRAF1LYN | |
| SCHEMBL19376885 | 0.81 | RAB9A (0.54) | NPC1RAB9ACSF1RRAF1EPHX1 | |
| SCHEMBL19376876 | 0.80 | RAF1 (0.61) | NPC1RAB9ACSF1RRAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | claimed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | claimed |
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | disclosed |
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | disclosed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | disclosed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | ABL1, FLT3, MERTK | NPC1 3572/4885RAB9A 3296/4885CSF1R 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.